Pressure BioSciences' pressure cycling technology on display at international cancer conference

Pressure BioSciences Inc’s (OTCMKTS:PBIO) patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the International Gynecologic Cancer Society in Brazil. 

The company’s PCT platform was used as part of a new process for analyzing proteins for cancer biopsy samples, the company said in a statement Tuesday. 

The idea, according to the chair of OB-GYN at Inova Fairfax Hospital, Larry Maxwell, is that chemotherapy is often being replaced by biologic therapeutics in the treatment of ovarian cancers. Biopsy analysis is central to diagnosis and the method of treatment. 

“Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies,” Maxwell said in a statement. “Technology provided by Pressure BioSciences has become an essential requirement for our novel workflow in meeting our goals.”

READ: Pressure BioSciences’ pressure cycling technology prominently featured at a major conference in Australia

Maxwell led the Innova group’s presentation at the September 21 event, which was entitled Interim Analysis of Ovarian Cancer by the US National Cancer MOONSHOT’S Tri-Federal (DOD/NCI/VA) Applied Proteogenomic Organizational Learning and Outcomes (APOLLO) Research Network. 

The new workflow utilizes a laser microdissection platform developed by Leica Microsystems, then delivers cells into Pressure Biosciences’ BaroCycler system, which prepares the sample by facilitating rapid and efficient high-quality cellular protein release. The proteins are then analyzed by a ThermoFisher Scientific mass spectrometry instrument, a device that measures the ratio of mass to change in ions. 

“We were delighted to see PBI’s Barocycler system featured in its pivotal position in this important new tumor processing workflow,” CEO Richard Schumacher said in a statement. 

“We believe that the number of laboratories worldwide performing laser microdissection followed by mass spectrometric analyses will increase at a steady but significant rate, that our Barocycler system will remain a critical part of this workflow, and that the adoption of this novel new workflow should result in a measurable increase in Barocycler sales over the coming months and years.”

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors